Preclinical work has shown KRAS inhibition can delay cancer onset and extend survival in mice with pancreatic intraepithelial neoplasia lesions.

Researchers also reported results from a separate trial of a gene therapy the company is developing for PKP2-related arrhythmogenic cardiomyopathy.

The US Food and Drug Administration has cleared radiopharmaceutical company Aktis Oncology to begin trials of its B7-H3-targeting miniprotein radioconjugate, the company announced this week. Aktis ...

An imaging sub-study of the ASO in hypertriglyceridemia patients presented at ACC highlights uncertainty about the drug's impact on cardiac outcomes.

An exclusive option and license deal AviadoBio struck with Astellas Pharma in 2024 has expired, but Astellas Pharma remains a shareholder in the firm.